This finding was inconsistent with the conclusions drawn from previous meta-analyses (Agostinetto et al., 2021), which indicated that CDK4/6 inhibitors confer no benefit on IDFS, DRFS, or OS in HR-positive/HER2-negative early breast cancer patients. Here, ERBB2 is linked to breast cancer.